Patent · US Active

CFTR mRNA compositions and related methods and uses

US9181321B2 · kind B2 · utility

37Cited by

205References

18Claims

0Family size

Assignees

SHIRE HUMAN GENETIC THERAPIES, INC. · US
ethris GmbH · DE

Inventors

Michael Heartlein · Boxborough, US
Braydon Charles Guild · Concord, US
Frank DeRosa · Lexington, US
Carsten Rudolph · Krailling, DE
Christian Plank · Wien, AT
Lianne Smith · Lexington, US

Key dates

Filing date	Jun 17, 2014
Grant date	Nov 10, 2015
Priority date	—
Expiry date	Jun 17, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y306/03049
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Materials, formulations, production methods, and methods for delivery of CFTR mRNA for induction of CFTR expression, including in the mammalian lung are provided. The present invention is particularly useful for treating cystic fibrosis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.